首页|芪苈强心胶囊联合西药治疗慢性心力衰竭疗效及其对心功能、炎性因子、纤维化指标的影响

芪苈强心胶囊联合西药治疗慢性心力衰竭疗效及其对心功能、炎性因子、纤维化指标的影响

扫码查看
目的 探讨芪苈强心胶囊联合西药治疗慢性心力衰竭(chronic heart failure,CHF)的效果,观察其对心功能、炎性因子及纤维化指标水平的影响。方法 选取 90 例CHF患者并利用随机数字表法将其分为对照组和观察组,每组各 45 例。对照组采用常规西药治疗,观察组加用芪苈强心胶囊,并比较治疗8 周后两组的疗效。结果 治疗 8 周后两组患者的各症状积分均显著降低,且观察组气喘、肢体浮肿及畏寒肢冷的症状积分均较对照组显著降低(均P<0。05)。两组患者治疗8 周后的心功能较治疗前显著改善(P<0。05);观察组左心室射血分数(LVEF)、每搏输出量(stroke volume,SV)显著高于对照组,而左心室舒张末期内径(left ventricular end-diastolic diameter,LVEDD)、左心室收缩末期内径(left ventricular end-systolic diameter,LVESD)显著低于对照组(均P<0。01)。治疗后观察组血清肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、NT-proBNP、超敏 C 反应蛋白(hypersensitive C-reactive protein,hs-CRP)水平显著低于对照组(均P<0。01);观察组血清转化生长因子β1(transforming growth factor-β1,TGF-β1)、成纤维细胞生长因子-23(fibroblasts growth factor-23,FGF-23)、基质金属蛋白酶组织抑制剂-1(tissue inhibitor of matrix metallo protease-1,TIMP-1)水平相较于对照组显著降低(均P<0。05)。治疗后观察组总有效率显著高于对照组(93。33%vs。68。89%),且差异有统计学意义(P<0。05)。结论 临床上应用芪苈强心胶囊联合西药治疗CHF较常规西药治疗能进一步减轻患者炎症性损伤并改善心功能,从而有效缓解CHF。
Efficacy of Qili Qiangxin Capsules combined with western medicine in treating chronic heart failure and its impact on cardiac function,inflammatory factors and fibrosis indexes
Objective To investigate the efficacy of Qili Qiangxin Capsules combined with western medicine in the treatment of chronic heart failure(CHF),and to observe its impact on cardiac function,inflammatory factors and fibrosis index levels.Methods Ninety CHF patients were selected;by using the random number table method,they were divided into control group and observation group,with 45 cases in each group.The control group conventionally adopted western medicine therapy,while the observation group was additionally administered Qili Qiangxin Capsules.The efficacy was compared after 8 weeks of treatment between the two groups.Results After 8 weeks of treatment,the symptom scores of patients in the two groups all significantly decreased,while the scores for asthma,limb edema and chills with cold extremities in the observation group were all significantly lower than those in the control group(all P<0.05).The cardiac function of both groups significantly improved after 8 weeks of treatment as compared to before(P<0.05);LVEF and stroke volume(SV)in the observation group were significantly higher than those in the control group,while left ventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter(LVESD)were significantly lower than those in the control group(both P<0.01).After treatment,the levels of serum tumor necrosis factor-α(TNF-α),NT-proBNP and hypersensitive C-reactive protein(hs-CRP)in the observation group were significantly lower than those in the control group(all P<0.01);the levels of serum transforming growth factor-β1(TGF-β1),fibroblasts growth factor-23(FGF-23)and tissue inhibitor of matrix metallo protease-1(TIMP-1)in the observation group were significantly reduced compared with those in the control group(all P<0.05).The total effective rate in the observation group after treatment was significantly higher than that in the control group(93.33%vs.68.89%),and the difference was statistically significant(P<0.05).Conclusion Compared with conventional western medicine therapy,the clinical application of Qili Qiangxin Capsules combined with western medicine in the treatment of CHF could further reduce inflammatory damage and improve cardiac function,which effectively relieves CHF.

Qili Qiangxin Capsulechronic heart failurecardiac functionfibrosis indexinflammatory factor

刘莹、刘耀武、罗国帅

展开 >

473000 河南 南阳,南阳医学高等专科学校第二附属医院内科

芪苈强心胶囊 慢性心力衰竭 心功能 纤维化指标 炎性因子

2024

实用心电学杂志
江苏大学

实用心电学杂志

影响因子:0.648
ISSN:2095-9354
年,卷(期):2024.33(5)